Future Directions and Unmet Needs in Chronic GvHD
Watch
Manageable Adverse Effects Associated With Treatments for EGFR+ NSCLC
Practical Implications of the RELAY Trial in EGFR+ NSCLC
Emerging Agents for the Treatment of Chronic GvHD
Steroid-Refractory GvHD: Treatment With JAK Inhibitors
Treatment Options for EGFR+ NSCLC
Molecular Testing for Newly Diagnosed NSCLC
Treatment Options for Chronic GvHD
Improved Outcomes for Patients With EGFR+ NSCLC
Definition of GvHD
Case Overview: 49-Year-Old Man With Chronic GvHD
A 68-Year-Old Man With Metastatic EGFR+ NSCLC
A 49-Year-Old Man With Steroid-Refractory Chronic Graft Versus Host Disease
Corey S. Cutler, MD, MPH, FRCPC, provides insight on the case of a 49-year-old man with chronic GVHD and reviews current and emerging treatment options for disease management.
John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.
Exploring Current and Upcoming Therapies for Hepatocellular Carcinoma
David J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.
Tivozanib Could Be Evaluated in Combination Regimens for Renal Cell Carcinoma
Vivek Subbiah, MD, discusses the potential to combine tivozanib with other agents, particularly ipilimumab, as treatment of patients with renal cell carcinoma.
Pembrolizumab Shows Durable Response in Advanced Unresectable Anal Cancer
Van K. Morris, MD, discusses the findings of the KEYNOTE-158 trial, which evaluated pembrolizumab in advanced solid tumors in relation to patients with advanced unresectable anal cancer.
Role of Multidisciplinary Management in mCRPC
Importance of Bone Health Agents in mCRPC Management
Combination of Radium-223 With Other Novel Agents in mCRPC
Radium 223: Counseling Patients With mCRPC
Management of mCRPC: Radium-223
Approaching Therapy for mCRPC
Therapeutic Options for mCRPC
Standard of Care for mCRPC
Case Overview: 69-Year-Old Man With Advanced CRPC
A 69-Year-Old Man With Advanced Castrate-Resistant Prostate Cancer
Jorge Garcia, MD, FACP, provides insight on the case of a 69-year-old man with mCRPC and assesses the classes of agents currently available as treatment options.
Analyzing CAR T-Cell Neurotoxicity in Adult Patients With ALL
Jae Park, MD, discusses adverse events associated with chimeric antigen receptor T-cell therapies, such as neurotoxicity, for patients with acute lymphocytic leukemia.
Treatment Options Evolve for Patients With Desmoid Fibromatosis
Neeta Somaiah, MD, discusses the evolution of treatment options for patients with a unique sarcoma.
Next Steps in Relapsed/Refractory Mantle Cell Lymphoma
